O-methylguanine-DNA methyltransferase immunoexpression in a double pituitary adenoma: Case report

Neurosurgery

Volumn 66, Issue 2, 2010, Pages

  Mohammed, Safraz ^a   Cusimano, Michael D ^a   Scheithauer, Bernd W ^b   Rotondo, Fabio ^a   Horvath, Eva ^a   Kovacs, Kalman ^a,c  

^a ST MICHAEL'S HOSPITAL   (Canada)

^b MAYO CLINIC   (United States)

^c UNIVERSITY OF TORONTO   (Canada)

Author keywords

Double pituitary adenoma; Immunohistochemistry; O Methylguanine DNA methyltransferase; Pituitary

Indexed keywords

METHYLATED DNA PROTEIN CYSTEINE METHYLTRANSFERASE; OCTREOTIDE;

ADULT; ARTICLE; CASE REPORT; CLINICAL FEATURE; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; HYPOPHYSIS ADENOMA; IMMUNOHISTOCHEMISTRY; MALE; NUCLEAR MAGNETIC RESONANCE IMAGING; PRIORITY JOURNAL; PROTEIN EXPRESSION; TRANSSPHENOIDAL SURGERY; TREATMENT OUTCOME; TUMOR RECURRENCE;

ADENOMA; DNA MODIFICATION METHYLASES; DNA REPAIR ENZYMES; GROWTH HORMONE; HUMANS; HYPERPROLACTINEMIA; INSULIN-LIKE GROWTH FACTOR BINDING PROTEINS; KI-67 ANTIGEN; MALE; MIDDLE AGED; PITUITARY NEOPLASMS; TUMOR SUPPRESSOR PROTEINS;

EID: 75749123880     PISSN: 0148396X     EISSN: None     Source Type: Journal    
DOI: 10.1227/01.NEU.0000363852.77126.AD     Document Type: Article

References (18)

1. Kontogeorgos G, Scheithauer BW, Horvath E, et al. Double adenomas of the pituitary: a clinicopathological study of 11 tumors. Neurosurgery. 1992;31:840-849.
2. Meij BP, Lopes MB, Vance ML, Thorner MO, Laws ER Jr. Double pituitary lesions in three patients with Cushing's disease. Pituitary. 2000;3:159-168.
3. Ratliff JK, Oldfield EH. Multiple pituitary adenomas in Cushing's disease. J Neurosurg. 2000;93(5):753-761.
4. Kontogeorgos G, Kovacs K, Horvath E, Scheithauer BW. Multiple adenomas of the human pituitary. A retrospective autopsy study with clinical implications. J Neurosurg.1991;74(2):243-247.
5. Tomita T, Kuziez M, Watanabe I. Double tumors of anterior and posterior pituitary gland. Acta Neuropathol. 1981;54(2):161-164.
6. Scheithauer BW, Horvath E, Kovacs K, Laws ER Jr, Randall RV, Ryan N. Plurihormonal pituitary adenomas. Semin Diagn Pathol. 1986;3(1):69-82.
7. Kovacs K, Horvath E, Syro LV, et al. Temozolomide therapy in a man with an aggressive prolactin-secreting pituitary neoplasm: morphological findings. Hum Pathol. 2007;38(1):185-189.
8. Kovacs K, Scheithauer BW, Lombardero M, et al. MGMT immunoexpression predicts responsiveness of pituitary tumors to temozolomide therapy. Acta Neuropathol. 2008;115(2):261-262.
9. Syro LV, Uribe H, Penagos LC, et al. Antitumour effects of temozolomide in a man with a large, invasive prolactin-producing pituitary neoplasm. Clin Endocrinol (Oxf ). 2006;65(4):552-553.
10. Kannuki S, Matsumoto K, Sano T, Shintani Y, Bando H, Saito S. Double pituitary adenoma-two case reports. Neurol Med Chir (Tokyo). 1996;36(11):818-821.
11. Sano T, Horiguchi H, Xu B, et al. Double pituitary adenomas: six surgical cases. Pituitary. 1999;1(3-4):243-250.
12. Kovacs K, Horvath E: Effects of medical therapy on pituitary tumors. Ultrastruct Pathol. 2005;29(3-4):163-167.
13. Kaltsas GA, Mukherjee JJ, Plowman PN, Monson JP, Grossman AB, Besser GM. The role of cytotoxic chemotherapy in the management of aggressive and malignant pituitary tumors. J Clin Endocrinol Metab. 1998;83(12):4233-4238.
14. Mortini P, Barzaghi R, Losa M, Boari N, Giovanelli M. Surgical treatment of giant pituitary adenomas: strategies and results in a series of 95 consecutive patients. Neurosurgery. 2007;60(6):993-1004.
15. Fadul CE, Kominsky AL, Meyer LP, et al. Long-term response of pituitary carcinoma to temozolomide. Report of two cases. J Neurosurg. 2006;105(4):621-626.
16. Lim S, Shahinian H, Maya MM, Yong W, Heaney AP. Temozolomide: a novel treatment for pituitary carcinoma. Lancet Oncol. 2006;7(6):518-520.
17. Newlands ES, Stevens MF, Wedge SR, Wheelhouse RT, Brock C. Temozolomide: a review of its discovery, chemical properties, pre-clinical development and clinical trials. Cancer Treat Rev. 1997;23(1):35-61.
18. Payne MJ, Pratap SE, Middleton MR. Temozolomide in the treatment of solid tumours: current results and rationale for dosing/scheduling. Crit Rev Oncol Hematol. 2005;53(3):241-252.